MESOBLAST LTD- SPON ADR (MESO) Stock Price, Forecast & Analysis
NASDAQ:MESO • US5907174016
MESO Key Statistics, Chart & Performance
The current stock price of MESO is 16.89 USD. In the past month the price decreased by -4.25%. In the past year, price decreased by -5.64%.
MESO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MESO. When comparing the yearly performance of all stocks, MESO is one of the better performing stocks in the market, outperforming 70.47% of all stocks.
MESO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MESO. MESO has a bad profitability rating. Also its financial health evaluation is rather negative.
MESO Financial Highlights
Over the last trailing twelve months MESO reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 21.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| Debt/Equity | 0.12 |
MESO Forecast & Estimates
10 analysts have analysed MESO and the average price target is 18.46 USD. This implies a price increase of 9.27% is expected in the next year compared to the current price of 16.89.
For the next year, analysts expect an EPS growth of -279.39% and a revenue growth -23.22% for MESO
MESO Ownership
MESO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MESO
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Company Info
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000 AU
CEO: Silviu Itescu
Employees: 81
Phone: 61396396036
MESOBLAST LTD- SPON ADR / MESO FAQ
What does MESOBLAST LTD- SPON ADR do?
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
What is the current price of MESO stock?
The current stock price of MESO is 16.89 USD. The price decreased by -7.7% in the last trading session.
What is the dividend status of MESOBLAST LTD- SPON ADR?
MESO does not pay a dividend.
How is the ChartMill rating for MESOBLAST LTD- SPON ADR?
MESO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting MESO stock to perform?
10 analysts have analysed MESO and the average price target is 18.46 USD. This implies a price increase of 9.27% is expected in the next year compared to the current price of 16.89.
Can you provide the growth outlook for MESOBLAST LTD- SPON ADR?
The Revenue of MESOBLAST LTD- SPON ADR (MESO) is expected to decline by -23.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for MESOBLAST LTD- SPON ADR?
MESOBLAST LTD- SPON ADR (MESO) has a market capitalization of 2.18B USD. This makes MESO a Mid Cap stock.